Chemical: Drug
streptomycin

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for streptomycin

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA No VIP available GSTM1 non-null N/A N/A N/A
No VIP available CA VA GSTM1 null N/A N/A N/A
No VIP available CA No VIP available GSTT1 non-null N/A N/A N/A
No VIP available CA VA GSTT1 null N/A N/A N/A
No VIP available No VIP available VA NAT2 *4 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5 N/A N/A N/A
No VIP available No VIP available VA NAT2 *5B N/A N/A N/A
No VIP available No VIP available VA NAT2 *6 N/A N/A N/A
No VIP available No VIP available VA NAT2 *6A N/A N/A N/A
No VIP available No VIP available VA NAT2 *7 N/A N/A N/A
No VIP available No VIP available VA NAT2 *7A N/A N/A N/A
No VIP available CA VA STAT3 CTA N/A N/A N/A
No VIP available CA VA STAT3 TCG N/A N/A N/A
No VIP available CA VA STAT3 TTA N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1524107 NC_000007.13:g.22768219C>T, NC_000007.14:g.22728600C>T, NG_011640.1:g.6454C>T, NM_000600.4:c.211-93C>T, NM_001318095.1:c.-18-93C>T, NR_131935.1:n.-980G>A, XM_005249745.1:c.373-93C>T, XM_005249745.3:c.373-93C>T, XM_005249746.1:c.-18-93C>T, XM_011515390.1:c.211-93C>T, XM_011515391.1:c.-18-93C>T
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1695 NC_000011.10:g.67585218A>G, NC_000011.9:g.67352689A>G, NG_012075.1:g.6624A>G, NM_000852.3:c.313A>G, NP_000843.1:p.Ile105Val, XM_005273958.1:c.313A>G, XP_005274015.1:p.Ile105Val, rs1138257, rs11553891, rs17353321, rs17856342, rs2230827, rs4609, rs56971933, rs947894
A > G
SNP
I105V
No VIP available No Clinical Annotations available VA
rs2031920 NC_000010.10:g.135339845C>T, NC_000010.11:g.133526341C>T, NG_008383.1:g.3979C>T, NM_000773.3:c.-1055C>T, XM_005252665.1:c.-512C>T, rs3813868
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2066992 NC_000007.13:g.22768249G>T, NC_000007.14:g.22728630G>T, NG_011640.1:g.6484G>T, NM_000600.4:c.211-63G>T, NM_001318095.1:c.-18-63G>T, NR_131935.1:n.-1010C>A, XM_005249745.1:c.373-63G>T, XM_005249745.3:c.373-63G>T, XM_005249746.1:c.-18-63G>T, XM_011515390.1:c.211-63G>T, XM_011515391.1:c.-18-63G>T, rs17147236, rs58064907
G > T
SNP
No VIP available No Clinical Annotations available VA
rs2069837 NC_000007.13:g.22768027A>G, NC_000007.14:g.22728408A>G, NG_011640.1:g.6262A>G, NM_000600.4:c.211-285A>G, NM_001318095.1:c.-18-285A>G, NR_131935.1:n.-788T>C, XM_005249745.1:c.373-285A>G, XM_005249745.3:c.373-285A>G, XM_005249746.1:c.-18-285A>G, XM_011515390.1:c.211-285A>G, XM_011515391.1:c.-18-285A>G, rs111176548, rs16873259, rs3779040, rs56908115
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2227956 NC_000006.11:g.31778272G=, NC_000006.11:g.31778272G>A, NC_000006.12:g.31810495G=, NC_000006.12:g.31810495G>A, NG_011855.1:g.9564C=, NG_011855.1:g.9564C>T, NM_005527.3:c.1478C=, NM_005527.3:c.1478C>T, NP_005518.3:p.Thr493=, NP_005518.3:p.Thr493Met, NT_113891.2:g.3287853A=, NT_113891.2:g.3287853A>G, NT_113891.3:g.3287747A=, NT_113891.3:g.3287747A>G, NT_167244.1:g.3093033A=, NT_167244.1:g.3093033A>G, NT_167244.2:g.3143117A=, NT_167244.2:g.3143117A>G, NT_167245.1:g.3063859G=, NT_167245.1:g.3063859G>A, NT_167245.2:g.3058274G=, NT_167245.2:g.3058274G>A, NT_167248.1:g.3071920A=, NT_167248.1:g.3071920A>G, NT_167248.2:g.3066324A=, NT_167248.2:g.3066324A>G, XM_005249070.1:c.1670C=, XM_005249070.1:c.1670C>T, XM_005249070.3:c.1670C=, XM_005249070.3:c.1670C>T, XM_005249071.1:c.1478C=, XM_005249071.1:c.1478C>T, XM_005249072.1:c.1478C=, XM_005249072.1:c.1478C>T, XM_005249073.1:c.1478C=, XM_005249073.1:c.1478C>T, XM_005249073.2:c.1478C=, XM_005249073.2:c.1478C>T, XM_005249074.1:c.1478C=, XM_005249074.1:c.1478C>T, XM_005272813.1:c.1670T=, XM_005272813.1:c.1670T>C, XM_005272814.1:c.1478T=, XM_005272814.1:c.1478T>C, XM_005272815.1:c.1478T=, XM_005272815.1:c.1478T>C, XM_005272816.1:c.1478T=, XM_005272816.1:c.1478T>C, XM_005272816.2:c.1478T=, XM_005272816.2:c.1478T>C, XM_005272817.1:c.1478T=, XM_005272817.1:c.1478T>C, XM_005274858.1:c.1478T=, XM_005274858.1:c.1478T>C, XM_005274859.1:c.1670T=, XM_005274859.1:c.1670T>C, XM_005274859.3:c.1670T=, XM_005274859.3:c.1670T>C, XM_005274860.1:c.1478T=, XM_005274860.1:c.1478T>C, XM_005274861.1:c.1478T=, XM_005274861.1:c.1478T>C, XM_005274861.2:c.1478T=, XM_005274861.2:c.1478T>C, XM_005274862.1:c.1478T=, XM_005274862.1:c.1478T>C, XM_005274970.1:c.1670C=, XM_005274970.1:c.1670C>T, XM_005274970.3:c.1670C=, XM_005274970.3:c.1670C>T, XM_005274971.1:c.1478C=, XM_005274971.1:c.1478C>T, XM_005274972.1:c.1478C=, XM_005274972.1:c.1478C>T, XM_005274973.1:c.1478C=, XM_005274973.1:c.1478C>T, XM_005274973.2:c.1478C=, XM_005274973.2:c.1478C>T, XM_005274974.1:c.1478C=, XM_005274974.1:c.1478C>T, XM_005275398.1:c.1478T=, XM_005275398.1:c.1478T>C, XM_005275399.1:c.1670T=, XM_005275399.1:c.1670T>C, XM_005275400.1:c.1478T=, XM_005275400.1:c.1478T>C, XM_005275401.1:c.1478T=, XM_005275401.1:c.1478T>C, XM_005275401.2:c.1478T=, XM_005275401.2:c.1478T>C, XM_005275402.1:c.1478T=, XM_005275402.1:c.1478T>C, XM_011514566.1:c.1478C=, XM_011514566.1:c.1478C>T, XM_011546311.1:c.1478T=, XM_011546311.1:c.1478T>C, XM_011547246.1:c.1478T=, XM_011547246.1:c.1478T>C, XM_011547247.1:c.1670T=, XM_011547247.1:c.1670T>C, XM_011547652.1:c.1478C=, XM_011547652.1:c.1478C>T, XM_011548238.1:c.1478T=, XM_011548238.1:c.1478T>C, XM_011548239.1:c.1670T=, XM_011548239.1:c.1670T>C, XP_005249127.1:p.Thr557=, XP_005249127.1:p.Thr557Met, XP_005249128.1:p.Thr493=, XP_005249128.1:p.Thr493Met, XP_005249129.1:p.Thr493=, XP_005249129.1:p.Thr493Met, XP_005249130.1:p.Thr493=, XP_005249130.1:p.Thr493Met, XP_005249131.1:p.Thr493=, XP_005249131.1:p.Thr493Met, XP_005272870.1:p.Met557=, XP_005272870.1:p.Met557Thr, XP_005272871.1:p.Met493=, XP_005272871.1:p.Met493Thr, XP_005272872.1:p.Met493=, XP_005272872.1:p.Met493Thr, XP_005272873.1:p.Met493=, XP_005272873.1:p.Met493Thr, XP_005272874.1:p.Met493=, XP_005272874.1:p.Met493Thr, XP_005274915.1:p.Met493=, XP_005274915.1:p.Met493Thr, XP_005274916.1:p.Met557=, XP_005274916.1:p.Met557Thr, XP_005274917.1:p.Met493=, XP_005274917.1:p.Met493Thr, XP_005274918.1:p.Met493=, XP_005274918.1:p.Met493Thr, XP_005274919.1:p.Met493=, XP_005274919.1:p.Met493Thr, XP_005275027.1:p.Thr557=, XP_005275027.1:p.Thr557Met, XP_005275028.1:p.Thr493=, XP_005275028.1:p.Thr493Met, XP_005275029.1:p.Thr493=, XP_005275029.1:p.Thr493Met, XP_005275030.1:p.Thr493=, XP_005275030.1:p.Thr493Met, XP_005275031.1:p.Thr493=, XP_005275031.1:p.Thr493Met, XP_005275455.1:p.Met493=, XP_005275455.1:p.Met493Thr, XP_005275456.1:p.Met557=, XP_005275456.1:p.Met557Thr, XP_005275457.1:p.Met493=, XP_005275457.1:p.Met493Thr, XP_005275458.1:p.Met493=, XP_005275458.1:p.Met493Thr, XP_005275459.1:p.Met493=, XP_005275459.1:p.Met493Thr, XP_011512868.1:p.Thr493=, XP_011512868.1:p.Thr493Met, XP_011544613.1:p.Met493=, XP_011544613.1:p.Met493Thr, XP_011545548.1:p.Met493=, XP_011545548.1:p.Met493Thr, XP_011545549.1:p.Met557=, XP_011545549.1:p.Met557Thr, XP_011545954.1:p.Thr493=, XP_011545954.1:p.Thr493Met, XP_011546540.1:p.Met493=, XP_011546540.1:p.Met493Thr, XP_011546541.1:p.Met557=, XP_011546541.1:p.Met557Thr, rs116591280, rs117465227, rs148468928, rs35842419, rs386561656, rs52829371, rs57160046
G > A
SNP
T493M
No VIP available No Clinical Annotations available VA
rs4646903 NC_000015.10:g.74719300A>G, NC_000015.9:g.75011641A>G, NG_008431.1:g.1759A>G, NM_000499.3:c.*1189T>C, NM_000499.4:c.*1189T>C, NM_000499.4:c.*947+242T>C, NM_001319216.1:c.*1189T>C, NM_001319216.1:c.*947+242T>C, NM_001319217.1:c.*1189T>C, NM_001319217.1:c.*947+242T>C, XM_005254185.1:c.*1189T>C, XM_005254186.1:c.*1189T>C, XM_005254187.1:c.*1189T>C, XM_005254188.1:c.*1189T>C, XM_005254189.1:c.*1189T>C, rs116877783, rs17861083, rs5030838
A > G
A > T
SNP
No VIP available No Clinical Annotations available VA
rs6413432 NC_000010.10:g.135348544T>A, NC_000010.11:g.133535040T>A, NG_008383.1:g.12678T>A, NM_000773.3:c.967+1143T>A, XM_005252665.1:c.1027+1143T>A
T > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Streptomycin Sesquisulfate Hydrate
  • Streptomycin Sulfate
  • Streptomycin Sulphate
  • Streptomycin a Sulfate
  • Streptomycin, Sulfate Salt
Trade Names
  • Kantrex
Brand Mixture Names
  • Aurex Rotenone Drops (Bacitracin + Penicillin + Rotenone + Streptomycin (Streptomycin Sulfate) + Undecylenic Acid)
  • Combiotic Vitamin Booster Pws (Calcium D-Pantothenate + Menadione + Nicotinic Acid + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Dp Booster Pws (D-Pantothenic Acid (Calcium D-Pantothenate) + Menadione + Nicotinic Acid + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Mastitis Care (Neomycin (Neomycin Sulfate) + Penicillin G Potassium + Polymyxin B (Polymyxin B Sulfate) + Streptomycin (Streptomycin Sulfate))
  • Medic Aid 2-50 (Menadione Sodium Bisulfite + Penicillin (Penicillin G Potassium) + Penicillin (Penicillin G Procaine) + Streptomycin Sulfate + Vitamin a + Vitamin D3)
  • Medivit (Calcium D-Pantothenate + Menadione + Nicotinamide + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin Sulfate + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Neospan Mastitis Treatment (Neomycin (Neomycin Sulfate) + Penicillin G Potassium + Polymyxin B (Polymyxin B Sulfate) + Streptomycin (Streptomycin Sulfate))
  • P.T. Booster (Calcium D-Pantothenate + Neomycin (Neomycin Sulfate) + Nicotinic Acid + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D3)
  • Parvit Plus (Penicillin G Procaine + Streptomycin Sulfate + Vitamin a + Vitamin C + Vitamin D3 + Vitamin E + Vitamin K1)
  • Pig Booster Liq Coop (Calcium D-Pantothenate + Neomycin + Nicotinic Acid + Streptomycin + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin B6 + Vitamin D)
  • Pig Starter Liq (Calcium D-Pantothenate + Neomycin Sulfate + Nicotinic Acid + Pyridoxine Hydrochloride + Streptomycin Sulfate + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D)
  • Pig Zest (Calcium D-Pantothenate + Neomycin (Neomycin Sulfate) + Nicotinic Acid + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D3)
  • Poly Tonine a Super Booster No.1 (Calcium D-Pantothenate + Menadione + Nicotinamide + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin Sulfate + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E (Dl-Alpha Tocopheryl Acetate))
  • Poly Vita Pen Strep (Calcium D-Pantothenate + Menadione Sodium Bisulfite + Nicotinic Acid + Penicillin G Procaine + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Polytonine a Super Booster No 1 Pws (Calcium D-Pantothenate + Menadione + Nicotinamide + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E (Dl-Alpha Tocopheryl Acetate))
  • Poultry Rx Pwr (Calcium D-Pantothenate + Folic Acid + Menadione Sodium Bisulfite + Nicotinic Acid + Penicillin G Potassium + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin B6 + Vitamin D3 + Vitamin E)
  • Previte (Neomycin (Neomycin Sulfate) + Selenium (Selenium Sulfide) + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin D + Vitamin E + Vitamin K1)
  • Scour Bolus Plus (Calcium Carbonate + Magnesium Oxide + Menadione (Menadione Sodium Bisulfite) + Neomycin (Neomycin Sulfate) + Potassium Acetate + Sodium Acetate + Sodium Chloride + Streptomycin (Streptomycin Sulfate) + Sulfamerazine + Sulfamethazine + Sulfanilamide + Sulfathiazole + Vitamin a + Vitamin D)
  • Stimu-Pig (Calcium D-Pantothenate + Neomycin (Neomycin Sulfate) + Nicotinic Acid + Pyridoxine Hydrochloride + Streptomycin (Streptomycin Sulfate) + Vitamin a + Vitamin B1 + Vitamin B12 + Vitamin B2 + Vitamin D3)
  • Streptocilline - Sp Pws (Calcium D-Pantothenate + Menadione + Nicotinamide + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin Sulfate + Thiamine Hydrochloride + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E)
  • Sul Dyo Strep (Aluminum Hydroxide + Kaolin + Pectin + Streptomycin Sulfate + Sulfamethazine)
  • Sulectim Plus Scour Boluses (Calcium Carbonate + Magnesium Oxide + Menadione Sodium Bisulfite + Neomycin (Neomycin Sulfate) + Potassium Acetate + Sodium Acetate + Sodium Chloride + Streptomycin (Streptomycin Sulfate) + Sulfamerazine + Sulfamethazine + Sulfanilamide + Sulfathiazole Sodium + Vitamin a + Vitamin D)
  • Vibiomed Fmx (Calcium D-Pantothenate + Dl-Alpha Tocopheryl Acetate + Menadione + Nicotinamide + Penicillin G Potassium + Pyridoxine Hydrochloride + Streptomycin Sulfate + Vitamin a + Vitamin B12 + Vitamin B2 + Vitamin D3)

PharmGKB Accession Id

PA451512

Type(s):

Drug

Description

Streptomycin is an aminoglycoside antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by binding to the 30S ribosomal subunit of susceptible organisms and disrupting the initiation and elongation steps in protein synthesis. It is bactericidal due to effects that are not fully understood.

Source: Drug Bank

Indication

For the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

Source: Drug Bank

Pharmacology

Streptomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Absorption

Rapidly absorbed after intramuscular injection with peak serum concentrations attained after 1 - 2 hours. Not absorbed in the GI tract.

Source: Drug Bank

Half-Life

5 - 6 hours in adults with normal renal function

Source: Drug Bank

Toxicity

Nephrotoxic and ototoxic potential. Nephrotoxicity is caused by accumulation of the drug in proximal renal tubular cells, which results in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild and reversible. Streptomycin is the least nephrotoxic of the aminoglycosides owing to the small number of cationic amino groups in its structure. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear. Accumulation causes irreversible damage to hair cells of the cochlea or summit of the ampullar cristae of the vestibular complex. High frequency hearing loss precedes low frequency hearing loss. Further toxicity may result in retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.
LD50=430 mg/kg (Orally in rats with Streptomycin Sulfate); Side effects include nausea, vomiting, and vertigo, paresthesia of face, rash, fever, urticaria, angioneurotic edema, and eosinophilia.

Source: Drug Bank

Route of Elimination

Small amounts are excreted in milk, saliva, and sweat. Streptomycin is excreted by glomerular filtration.

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H39N7O12

Source: Drug Bank

Isomeric SMILES

C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)NC(=N)N)O)NC(=N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O

Source: OpenEye

Canonical SMILES

CN[C@H]1[C@H]

Source: Drug Bank

Average Molecular Weight

581.5741

Source: Drug Bank

Monoisotopic Molecular Weight

581.265669747

Source: Drug Bank

SMILES

CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]2NC(N)=N)O[C@@H](C)[C@]1(O)C=O

Source: Drug Bank

InChI String

InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Interactions

Interaction Description
bumetanide - streptomycin Increased ototoxicity (source: Drug Bank )
bumetanide - streptomycin Increased ototoxicity (source: Drug Bank )
cefotaxime - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefotaxime - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefotetan - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
cefoxitin - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
ceftazidime - streptomycin Increased risk of nephrotoxicity (source: Drug Bank )
ethacrynic acid - streptomycin Increased ototoxicity (source: Drug Bank )
ethacrynic acid - streptomycin Increased ototoxicity (source: Drug Bank )
furosemide - streptomycin Increased ototoxicity (source: Drug Bank )
furosemide - streptomycin Increased ototoxicity (source: Drug Bank )
ticarcillin - streptomycin Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to streptomycin: 23

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Analysis of IL-6, STAT3 and HSPA1L Gene Polymorphisms in Anti-Tuberculosis Drug-Induced Hepatitis in a Nested Case-Control Study. PloS one. 2015. Wang Jing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study. PloS one. 2015. He Lei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinburgh, Scotland). 2014. Singla Neha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nature genetics. 2014. Casali Nicola, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. Journal of clinical pharmacy and therapeutics. 2012. Monteiro T P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2E1, GSTM1 and GSTT1 genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study. Journal of clinical pharmacy and therapeutics. 2012. Tang S-W, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Molecular diagnosis & therapy. 2012. Costa Gustavo N O, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Annals of hepatology. 2012. Lv Xiaozhen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between CYP2E1 polymorphism and increase of ALT activity during therapy of patients with pulmonary tuberculosis. Bulletin of experimental biology and medicine. 2011. Kudryashov A V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Memórias do Instituto Oswaldo Cruz. 2011. Teixeira Raquel Lima de Figueiredo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In vivo (Athens, Greece). 2011. Sotsuka Takayo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug safety : an international journal of medical toxicology and drug experience. 2010. Youngster Ilan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. Journal of clinical pharmacy and therapeutics. 2010. Chatterjee S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans. Tuberculosis (Edinburgh, Scotland). 2010. Kim Sang-Heon, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients. The Journal of international medical research. 2010. Wang T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug discovery and natural products: end of an era or an endless frontier?. Science (New York, N.Y.). 2009. Li Jesse W-H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver international : official journal of the International Association for the Study of the Liver. 2008. Leiro Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. The Journal of toxicological sciences. 2008. Fukino Katsumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs. The Medical journal of Malaysia. 2007. Tan W C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adverse reactions to first-line antituberculosis drugs. Expert opinion on drug safety. 2006. Forget Eric J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. Journal of gastroenterology and hepatology. 2001. Roy B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2000. Ohno M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. British medical journal. 1976. Chan T K, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
39822-0706-1
DrugBank:
DB01082
PDB:
SRY
ChEBI:
17076
KEGG Compound:
C00413
PubChem Compound:
19649
PubChem Substance:
3703
46506845
Drugs Product Database (DPD):
2243660
ChemSpider:
18508
HET:
SRY
Therapeutic Targets Database:
DAP000144
FDA Drug Label at DailyMed:
abd1f64e-4283-4370-aae8-3666316aa36e

Clinical Trials

These are trials that mention streptomycin and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.